Payment Terms | T/T, Western Union |
Supply Ability | 2000000pcs/month |
Delivery Time | 20-30days |
Packaging Details | 1pc/pouch, 25pcs/box |
Category | Cardiac |
Format | 4mm multiple |
Specimen | Whole Blood/Serum/Plasma |
Testing time | 5-15 minutes |
Shelf Life | 24 Months |
Application | Acute MI |
accurary | 98.55% |
Brand Name | New Life |
Model Number | cassette |
Certification | ISO13485,CE |
Place of Origin | China |
View Detail Information
Explore similar products
Portrable H FABP Rapid Test Blood Specimen 4mm Strip 5 Mins Reading Time
D-Dimer Cardiac Blood Tests Convenient One Step Quickly Operate For Vitro
Gold Colloidal Myoglobin Blood Test Home High Accuracy Kit Qualitative Detection
Lightweight CRP Test Kit 5-15 Mins Testing Time 10 μG/Ml Cutoff Rapid Diagnostic
Product Specification
Payment Terms | T/T, Western Union | Supply Ability | 2000000pcs/month |
Delivery Time | 20-30days | Packaging Details | 1pc/pouch, 25pcs/box |
Category | Cardiac | Format | 4mm multiple |
Specimen | Whole Blood/Serum/Plasma | Testing time | 5-15 minutes |
Shelf Life | 24 Months | Application | Acute MI |
accurary | 98.55% | Brand Name | New Life |
Model Number | cassette | Certification | ISO13485,CE |
Place of Origin | China | ||
High Light | heart disease blood test ,heart related blood tests |
One Step multiple cassette H-FABP/Cardiac Troponin I Combo cardiac blood Tests , gold colloidal method, quickly and easily
Intended Use:
The H-FABP/Cardiac Troponin I Combo Rapid Test Cassette (Whole Blood/Serum/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of human H-FABP and cardiac Troponin I (cTnI) in whole blood, serum or plasma as an aid in the diagnosis of myocardial infarction (MI).
Summary:
FABP is a newly introduced plasma marker of acute myocardial infarction (AMI). The plasma kinetics of FABP (15 kD) closely resemble those of myoglobin in that elevated plasma concentrations are found within 2 hours after AMI and return to normal generally within 18 to 24 hours. But the concentration of FABP in the skeletal muscle is 20 times lower than in cardiac tissue (for myoglobin the same content for cardiac and skeletal tissue), that makes FABP to be more cardiac specific than myoglobin. This makes FABP a useful biochemical marker for the early assessment or exclusion of AMI. FABP also appears to be a useful plasma marker for the estimation of myocardial infarct size. FABP is suitable for use as a standard in immunoassay for early detection of acute myocardial infarction, immunogen for antisera production, mass FABP standard, FABP biochemical and immunochemical studies, tracer for iodination. Cardiac Troponin I (cTnI) is a protein found in cardiac muscle with a molecular weight of 22.5 kDa.1 Troponin I is part of a three subunit complex comprising of Troponin T and Troponin C. Along with tropomyosin, this structural complex forms the main component that regulates the calcium sensitive ATPase activity of actomyosin in striated skeletal and cardiac muscle. After cardiac injury occurs, Troponin I is released into the blood 4-6 hours after the onset of pain. The release pattern of cTnI is similar to CK-MB, but while CK-MB levels return to normal after 72 hours, Troponin I remains elevated for 6-10 days, thus providing for a longer window of detection for cardiac injury. The high specificity of cTnI measurements for the identification of myocardial damage has been demonstrated in conditions such as the perioperative period, after marathon runs, and blunt chest trauma. cTnI release has also been documented in cardiac conditions other than acute myocardial infarction (AMI) such as unstable angina, congestive heart failure, and ischemic damage due to coronary artery bypass surgery. Because of its high specificity and sensitivity in the myocardial tissue, Troponin I has recently become the most preferred biomarker for myocardial infarction. The H-FABP/Cardiac Troponin I Combo Rapid Test Cassette (Whole Blood/Serum/Plasma) is a simple test that utilizes a combination of antibody coated particles and capture reagents to qualitatively detect H-FABP and cardiac Troponin I (cTnI) in whole blood, serum or plasma. The minimum detection level is 8 ng/mL H-FABP and 0.5 ng/mL Troponin I.
Test Principle:
The H-FABP/Cardiac Troponin I Combo Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative, membrane based immunoassay for the detection of H-FABP and cardiac Troponin I (cTnI) in whole blood, serum or plasma. The membrane is pre-coated with specific capture antibodies in each of the test line regions of the test. During testing, the whole blood, serum or plasma specimen reacts with the particle coated with specific antibodies. The mixture migrates upward on the membrane chromatographically by capillary action to react with specific capture reagents on the membrane and generate a colored line. The presence of this colored line in the specific test line region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.
TEST PROCEDURE
1. Bring the pouched test device to room temperature(15-30℃) prior to testing. Do not open the pouch until ready
to begin testing.
2. Remove the device from the sealed pouch and lay it on a flat and dry surface.
3. Using the provided pipette, add one drop of fresh specimen to the sample well.
4. Hold the buffer bottle vertically and add 1 drop to the sample well. /If using a pipette, change a new one to avoid cross-contamination. Draw and transfer 2-3 drops of buffer to the sample well.
5. Read the result between 15-20minutes. Do not read results after 20 minutes.
Limitation
PERFORMANCE CHARACTERISTICS
Sensitivity and Specificity
The Cardiac Combo Rapid Test Card has been evaluated with a leading commercial H-FABP/Troponin I EIA test using clinical specimens. The results show that relative to leading EIA test.
H-FABP Test vs. EIA | |||||||
Method | EIA | Total | |||||
H-FABP | Results | Positive | Negative | Results | |||
Positive | 54 | 1 | 55 | ||||
Test | |||||||
Negative | 0 | 422 | 422 | ||||
Total Results | 54 | 423 | 477 | ||||
Relative Sensitivity: 100% (93.4%-100.0%) * | |||||||
Relative Specificity: 99.8% (98.7%-99.9%)* | |||||||
Accuracy: 99.8% | (98.8% to 99.9%)* | (* 95% Confidence Interval) |
Troponin I Test vs. EIA
Method | EIA | Total | ||||||||
Negativ | ||||||||||
Results | Positive | Results | ||||||||
e | ||||||||||
cTnI Test | ||||||||||
Positive | 225 | 8 | 233 | |||||||
Negative | 3 | 505 | 508 | |||||||
Total Results | 228 | 513 | 741 | |||||||
Relative Sensitivity: 98.7% (96.2%- 99.7%)*
Relative Specificity: 98.4% (97.0%-99.3%)*
Accuracy: 98.5% (97.4%-99.3%)* (* 95% Confidence Interval)
ORIENT NEW LIFE MEDICAL CO., LTD. | |
Contact: | Jerry Meng |
Email: | Jerry @ newlifebiotest .com |
Tel. | +86 18657312116 |
SKYPE | enetjerry |
Company Details
Business Type:
Manufacturer,Exporter
Year Established:
2009
Total Annual:
10,000,000-15,000,000
Employee Number:
200~300
Ecer Certification:
Active Member
Established in 2009, Orient New Life Medical Co., Ltd., is specialized in high-tech biological diagnostic test development, research and production, as well as high-tech medical device development, research and production. New Life has built up two production base, which produce biological diagnosti... Established in 2009, Orient New Life Medical Co., Ltd., is specialized in high-tech biological diagnostic test development, research and production, as well as high-tech medical device development, research and production. New Life has built up two production base, which produce biological diagnosti...
Get in touch with us
Leave a Message, we will call you back quickly!